Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDS00319

Target Information
NameHIV-1 protease    
Type of targetSuccessful target    
SynonymsHIV-1 Retropepsin    
HIV-1 peptidase    
Retropepsin    
DiseaseHuman immunodeficiency virus [HIV] disease
[ICD9: 279.3   ICD10: D84.9]
[1][2][3]
Drug(s)AtazanavirApprovedHIV infection[3]
DarunavirApprovedHIV infection[4]
FosamprenavirApprovedHIV infection[5]
LopinavirApprovedHIV infection[6]
NelfinavirApprovedHIV infection[7]
TipranavirApprovedHIV infection[8]
BioChemical ClassProtease    
EC NumberEC 3.4.23.16
UniProt IDO09807
O90777
SequencePQITLWQRPVVIIKIEGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVKQYD QILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF
Related US Patent6,455,587
6,506,786
6,528,532
6,608,100
6,610,689
6,613,743
6,613,764
6,617,350
6,632,816
6,673,821
6,677,367
Target ValidationClick to Find Target Validation Information.    
QSAR ModelClick to Find Target QSAR Model.    
InhibitorAtazanavir[3]
BMS-232632[9]
Darunavir[4]
Fosamprenavir[5]
Lopinavir[6]
Nelfinavir[7]
Tipranavir[8]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther. 2001 Dec;6(4):201-29. To Reference
Ref 2Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):307-17. To Reference
Ref 3Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs. 2002 Sep;11(9):1295-301. To Reference
Ref 4Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. To Reference
Ref 5Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother. 2009 Aug;64(2):398-410. Epub 2009 Jun 10. To Reference
Ref 6HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9. To Reference
Ref 7Nelfinavir, a new protease inhibitor: early clinical results. AIDS. 1999 Sep;13 Suppl 1:S41-8. To Reference
Ref 8Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients. Curr HIV Res. 2009 Jul;7(4):425-33. To Reference
Ref 9Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis. 2001 Apr 1;183(7):1126-9. Epub 2001 Mar 1. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543